医用食品用于所述的治疗脑的发育-基于通过调节的神经精神疾病甘氨酸和谷胱甘肽途径

广东省科技图书馆(汇编整理) 2017/9/7 16:34:29
字体 分享
标题(翻译):MEDICAL FOODS FOR THE TREATMENT OF DEVELOPMENTALLY-BASED NEUROPSYCHIATRIC DISORDERS VIA MODULATION OF BRAIN GLYCINE AND GLUTATHIONE PATHWAYS 摘要:Describe herein are medical foods, pharmaceutical compositions, methods of compounding them, and method of using them for the treatment of developmentally-based neuropsychiatric disorders including particularly autism, ADHD, and persistent developmental disorders. The medical foods and pharmaceutical compositions typically include a methylglycine compound or precursor compound and an acetylcysteine compound or precursor compound. These methylglycine and acetylcysteine compounds may be prepared for sustained release or delivery. In some variations, a method of treating a developmentally-based neuropsychiatric disorder includes first determining if a patient is at risk for such a disorder by examining either or both phenotypical and genotypical biomarkers. The biomarkers may be used to tailor the dose to be delivered by the medial food or pharmaceutical composition. 摘要(翻译):本文描述的是医用食品,药物组合物,配制它们的方法,和使用它们的方法,用于所述的治疗; 受发育-基神经精神疾病尤其包括孤独症,ADHD,和持续发育障碍。所述的医疗食品和药物组合物典型地包括一种甲基甘氨酸化合物或前体化合物和一种乙酰半胱氨酸化合物或前体化合物。这些甲基甘氨酸和乙酰半胱氨酸的化合物可以制备用于缓释或输送。在一些变化,治疗的受发育-基的神经精神紊乱的方法,包括第一确定如果病人是在用于这种风险一种通过检查障碍的任一个或两个表型和genotypical生物标志物。该生物标志物可被使用来调制该剂量以被输送通过该内侧的食品或药物组合物。 公开(公告)号:WO2012024293A3 公开(公告)日:2012-06-14 申请号:WOUS11047913 申请日:2011-08-16 申请人:GENOMIND LLC; LOMBARD Jay L
XML 地图 | Sitemap 地图